48,830
edits
Difference between revisions of "Liposarcoma"
Jump to navigation
Jump to search
no edit summary
| (One intermediate revision by the same user not shown) | |||
| Line 22: | Line 22: | ||
| Symptoms = | | Symptoms = | ||
| Prevalence = most common retroperitoneal sarcoma, uncommon overall | | Prevalence = most common retroperitoneal sarcoma, uncommon overall | ||
| Bloodwork = | | Bloodwork = D-dimer elevated | ||
| Rads = thick septae or nodules in a fatty appearing lesion | | Rads = thick septae or nodules in a fatty appearing lesion | ||
| Endoscopy = | | Endoscopy = | ||
| Line 38: | Line 38: | ||
**Retroperitoneal: poor. | **Retroperitoneal: poor. | ||
**Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal | last1 = Lietman | first1 = SA. | last2 = Barsoum | first2 = WK. | last3 = Goldblum | first3 = JR. | last4 = Marks | first4 = KE. | last5 = Mascha | first5 = E. | last6 = Sundaram | first6 = M. | last7 = Muschler | first7 = G. | title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. | journal = Orthopedics | volume = 30 | issue = 3 | pages = 227-34 | month = Mar | year = 2007 | doi = | PMID = 17375550 }}</ref> | **Extremity: good - disease specific 5-year survival ~ 92%.<ref>{{Cite journal | last1 = Lietman | first1 = SA. | last2 = Barsoum | first2 = WK. | last3 = Goldblum | first3 = JR. | last4 = Marks | first4 = KE. | last5 = Mascha | first5 = E. | last6 = Sundaram | first6 = M. | last7 = Muschler | first7 = G. | title = A 20-year retrospective review of surgically treated liposarcoma at the Cleveland Clinic. | journal = Orthopedics | volume = 30 | issue = 3 | pages = 227-34 | month = Mar | year = 2007 | doi = | PMID = 17375550 }}</ref> | ||
**D-dimer (serum) useful; elevated levels in keeping with liposarcoma. | |||
***Cut-off value 0.41 μg/ml for metastasis: sensitivity 0.83 and specificity 0.57.<ref name=pmid22044610>{{cite journal |authors=Morii T, Mochizuki K, Tajima T, Ichimura S, Satomi K |title=D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma |journal=BMC Musculoskelet Disord |volume=12 |issue= |pages=250 |date=November 2011 |pmid=22044610 |pmc=3226444 |doi=10.1186/1471-2474-12-250 |url=}}</ref> | |||
***Cut-off value 0.80 μg/ml for total survival: sensitivity 0.80 and specificity 0.75.<ref name=pmid22044610/> | |||
Notes: | Notes: | ||